New Research Suggests Notch Inhibitor May Be Effective in Treatment-Resistant Breast Cancers

A collaborative study among LSU Health New Orleans School of Medicine, the University of Rochester, and Cellestia Biotech AG, a biopharmaceutical company headquartered in Basel, Switzerland, provides compelling evidence that combining an investigational oral drug with standard-of-care medications reverts hormone resistance and increases Rx effectiveness in experimental models of estrogen-receptor positive (ER+) and triple-negative breast cancers (TNBC), respectively. The findings were published online in MDPI Cancers, on August 3, 2023 and are available here. The open-access article is titled “The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer.”